# Elysium Health

> Elysium Health is a New York-based cellular health company that turns peer-reviewed aging research into consumer products. Founded in 2014 by entrepreneur Eric Marcotulli, operator Dan Alminana, and MIT aging biologist Leonard Guarente, it pairs a scientific advisory board stacked with Nobel laureates with a direct-to-consumer model. Its flagship supplement Basis raises NAD+ levels tied to cellular energy, and its Index test estimates biological age from a saliva sample using epigenetic methylation analysis.

- **Founded:** 2014
- **Headquarters:** New York, United States
- **Founders:** Eric Marcotulli (Co-Founder & CEO), Dan Alminana (Co-Founder & COO), Leonard Guarente (Co-Founder & Chief Scientist)
- **Team size:** Approximately 80 employees
- **Products:** Basis, Index, Matter, Signal, Format
- **Notable:** Built a scientific advisory board of 25+ researchers including multiple Nobel laureates, Launched Basis in 2015, one of the first consumer NAD+ precursor supplements backed by a clinical trial, Launched Index in 2019, bringing epigenetic biological-age testing direct to consumers

## Products & services

- **Basis** — Flagship daily supplement combining nicotinamide riboside and pterostilbene, clinically shown to raise NAD+ levels tied to cellular energy and repair. Launched 2015.
- **Index** — At-home epigenetic test that estimates biological age from a saliva sample using methylation analysis (APEX platform), reporting biological ages across multiple body systems. Launched 2019.
- **Matter** — Brain health supplement with a B-vitamin complex aimed at slowing age-related brain atrophy, developed with University of Oxford researchers. Launched 2020.
- **Signal** — Supplement designed to support metabolic function by replenishing declining metabolites.
- **Format** — Immune system support supplement. Launched 2021.
- **Mosaic** — Supplement targeting skin aging and skin barrier function. Launched 2023.
- **Vision** — Eye health and macular support supplement. Launched 2024.

## Achievements

- Built a scientific advisory board of 25+ researchers including multiple Nobel laureates
- Launched Basis in 2015, one of the first consumer NAD+ precursor supplements backed by a clinical trial
- Launched Index in 2019, bringing epigenetic biological-age testing direct to consumers
- Initiated a Phase II Basis trial at Mayo Clinic for post-cardiac-surgery kidney injury
- Raised $71.2M total across Series B and C funding
- Prevailed in nicotinamide riboside patent litigation, with dismissal affirmed by the Federal Circuit in 2023

## Latest updates

- **2024** — Launched Vision, an eye health and macular support supplement.
- **2023** — Launched Mosaic for skin aging; Federal Circuit affirmed dismissal of the nicotinamide riboside patent claims against the company.
- **2021** — Closed roughly $71.2M cumulative funding; launched Format for immune support.
- **2020** — Initiated Phase II clinical trial at Mayo Clinic evaluating Basis for acute kidney injury prevention; launched Matter brain-health supplement.

## Links

- Website: https://www.elysiumhealth.com
- LinkedIn: https://www.linkedin.com/company/elysium-health
- Twitter/X: https://twitter.com/elysiumhq
- YouTube: https://www.youtube.com/c/ElysiumHealth
- Instagram: https://www.instagram.com/elysiumhealth/
- Facebook: https://www.facebook.com/elysiumhealth/

---

Profile page: https://yespress.io/elysium-health
Published by YesPress — https://yespress.io
Last updated: 2026-06-15